Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07985045 Alone and in Combination in Advanced Solid Tumors
NCT06704724Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Dec 2024
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of pf-07985045 in solid tumor, non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and 1 more (12 arms), sponsored by Pfizer. Primary endpoints: Incidence of Adverse Events, Number of participants with laboratory abnormalities and 2 more. Started Dec 2024; status: terminated.
02
Drugs
pf-07985045
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06704724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06704724.